Riociguat

Active ingredient: Riociguat

In short: Riociguat tablets are indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class . Riociguat tablets are indicated for the tr

Forms & strengthsTablets: film-coated, round, bi-convex: 0.5 mg, White coloured, round shaped, biconvex, film-coated tablets debossed with "M 0.5'' on one side and plain on other side. …
LabelZydus Pharmaceuticals USA Inc
Label updatedSep 21, 2026

What is Riociguat used for?

Riociguat tablets are indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class .

Riociguat tablets are indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on riociguat tablets monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%) .

âš  Boxed warning (FDA's strongest warning)

Riociguat is contraindicated for use during pregnancy because it may cause fetal harm based on animal data [see Contraindications (4.1), Warnings and Precautions (5.1), and Use in Specific Populations (8.1)].

Exclude pregnancy prior to the start of treatment with riociguat. Advise use of effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with riociguat [see Dosage and Administration (2.3), Warnings and Precautions (5.1), and Use in Specific Populations (8.3)].

If pregnancy is detected, discontinue riociguat as soon as possible .

Riociguat dosage

The recommended starting dosage is 1 mg taken 3 times a day. For patients who may not tolerate the hypotensive effect of riociguat tablets, consider a starting dose of 0.5 mg taken three times a day. If systolic blood pressure remains greater than 95 mmHg and the patient has no signs or symptoms of hypotension, up-titrate the dose by 0.5 mg taken three times a day. Dose increases should be no sooner than 2 weeks apart. The dose can be increased to the highest tolerated dosage, up to a maximum of 2.5 mg taken three times a day. If at any time, the patient has symptoms of hypotension, decrease the dosage by 0.5 mg taken three times a day.

Crushed Tablets

For patients who are unable to swallow whole tablets, riociguat tablets may be crushed and mixed with water or soft foods (such as applesauce) immediately before administration .

If a dose is missed, advise patients to continue with the next regularly scheduled dose. In case riociguat tablets are interrupted for 3 days or more, re-titrate riociguat tablets.

Exclude pregnancy before initiating riociguat tablets. .

Consider titrating to dosages higher than 2.5 mg three times a day, if tolerated, in patients who smoke. A dose decrease may be required in patients who stop smoking .

Consider a starting dose of 0.5 mg, three times a day when initiating riociguat tablets in patients receiving strong cytochrome P450 (CYP) and P-glycoprotein/breast cancer resistance protein (P-gp/BCRP) inhibitors such as azole antimycotics (for example, ketoconazole, itraconazole) or HIV protease inhibitors (for example, ritonavir). Monitor for signs and symptoms of hypotension on initiation and on treatment with strong CYP and P-gp/BCRP inhibitors .

Discontinue sildenafil at least 24 hours prior to administering riociguat tablets .

Discontinue tadalafil at least 48 hours prior to administering riociguat tablets .

Consider initiating riociguat tablets at a starting dose of 0.5 mg in patients at risk of hypotension .Monitor for signs and symptoms of hypotension on initiation.

Discontinue riociguat tablets at least 24 hours prior to administering a PDE5-inhibitor .

Monitor for signs and symptoms of hypotension on initiation.

How to take Riociguat — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide). Embryo-Fetal Toxicity

Instruct patients on the risk of fetal harm when riociguat is used during pregnancy . Educate and counsel females of reproductive potential to use effective contraception prior to initiation of treatmentwith riociguat, during treatment,and for one month after stopping treatment. Instruct patients to contact their healthcare provider immediately if they suspect they may be pregnant. Educate and counsel females of reproductive potential on the use of emergency contraception in the event of unprotected sex or contraceptive failure. Advise pre-pubertal females to report any changes in their reproductive status immediately to their prescriber.

Lactation

Advise women not to breastfeed during treatment with riociguat .

Other Risks Associated with Riociguat

Inform patients of the contraindication of riociguat with nitrates or nitric oxide donors or PDE-5 inhibitors.

Advise patients about the potential risks/signs of hemoptysis and to report any potential signs of hemoptysis to their physicians.

Instruct patients on the dosing, titration, and maintenance of riociguat. …

Warnings & precautions

Do not take this medicine if: Use of riociguat is contraindicated in patients who are pregnant .

Co-administration of riociguat with nitrates or nitric oxide donors (such as amyl nitrite) in any form is contraindicated .

Concomitant administration of riociguat with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [ see Dosage and Administration (2.6), Drug Interactions (7.1)and

Clinical Pharmacology (12.2)].

Do not administer within 24 hours of sildenafil. Do not administer 24 hours before or within 48 hours after tadalafil.

Riociguat is contraindicated in patients with concomitant use of other soluble guanylate cyclase (s GC) stimulators .

Riociguat is contraindicated in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP).

Based on data from animal reproduction studies, riociguat may cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. The available human data for riociguat do not establish the presence or absence of major birth defects related to the use of riociguat. Counsel patients who can become pregnant on the potential risk to a fetus. Exclude pregnancy prior to initiation of treatment with riociguat. Advise females of reproductive potential to use effective contraception prior to initiation of treatment, during treatment with riociguat and for at least one month after the last dose. When pregnancy is detected, discontinue riociguat as soon as possible [see Dosage and Administration (2.3), Contraindications (4.1), and Use in Specific Populations (8.1, 8.3)].

Riociguat reduces blood pressure. …

Riociguat side effects

The following serious adverse reactions are discussed elsewhere in the labeling:

Embryo-Fetal Toxicity

Hypotension

Bleeding

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described below reflect exposure to riociguat in two, randomized, double blind, placebo-controlled trials in patients with inoperable or recurrent/persistent CTEPH (CHEST-1) and treatment naive or pre-treated PAH patients (PATENT-1). The population (riociguat: n = 490; Placebo: n = 214) was between the age of 18 and 80 years .

The safety profile of riociguat in patients with inoperable or recurrent/persistent CTEPH (CHEST-1) and treatment naive or pre-treated PAH (PATENT-1) were similar. Therefore, adverse drug reactions (ADRs) identified from the 12 and 16 week placebo-controlled trials for PAH and CTEPH respectively were pooled, and those occurring more frequently on riociguat than placebo (≥3%) are displayed in Table 1 below. Most adverse reactions in Table 1 can be ascribed to the vasodilatory mechanism of action of riociguat. The overall rates of discontinuation due to an adverse event in the pivotal placebo-controlled trials were 2.9% for riociguat and 5.1% for placebo (pooled data). …

Drug interactions

Other Soluble Guanylate Cyclase Stimulators: Co-administration of riociguat is contraindicated in patients with use of other soluble guanylate cyclase (sGC) stimulators .

Nitrates: Co-administration of riociguat with nitrates or nitric oxide donors (such as amyl nitrite) in any form is contraindicated because of hypotension

.

PDE Inhibitors: Co-administration of riociguat with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or theophylline), is contraindicated because of hypotension. Do not administer within 24 hours of sildenafil. Do not administer 24 hours before or within 48 hours after tadalafil .

Clinical experience with co-administration of riociguat and other phosphodiesterase inhibitors (for example, milrinone, cilostazole, roflumilast) is limited.

Smoking: Plasma concentrations in smokers are reduced by 50% to 60% compared to nonsmokers. Based on pharmacokinetic modeling, for patients who are smokers, doses higher than 2.5 mg three times a day may be considered in order to match exposure seen in nonsmoking patients. Safety and effectiveness of riociguat doses higher than 2.5 mg three times a day have not been established. A dose reduction should be considered in patients who stop smoking . …

About this medicine

Riociguat USP is a soluble guanylate cyclase stimulator tablet for oral administration. Riociguat USP is methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl (methyl) carbamate with the following structural formula:

C20H19FN8O2

Riociguat USP is a white to yellowish crystalline powder substance with a molecular weight of 422.42 g/mol. In solid form it is stable to temperature, light, and humidity. Freely soluble in Dimethyl sulphoxide, Soluble in N,N-Dimethyl formamide; Slightly soluble in tetrahydrofuran and insoluble in water Each round film-coated tablet contains (0.5 mg,1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg) riociguat USP. The inactive ingredients are croscarmellose sodium, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polysorbate 80, propylene glycol and titanium dioxide. Riociguat 1 mg, 1.5 mg, 2 mg and 2.5 mg tablets contain, in addition, ferric oxide yellow. Riociguat 2 mg and 2.5 mg tablets contain, in addition, ferric oxide red. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8092c64b-e240-43c3-9d2e-e0dd7708d96f. Read the full official label on DailyMed.

Related medicines

Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone